Cassava Sciences' stock fell after Phase 3 simufilam trial failed to meet key endpoints, prompting the discontinuation of its Alzheimer's studies.

Telsey Advisory Group analyst Joseph Feldman downgraded Five Below, Inc. FIVE from Outperform to Market Perform and lowered ...

Live Nation Entertainment LYV has outperformed the market over the past 15 years by 9.98% on an annualized basis producing an ...

Buying $100 In TTD: If an investor had bought $100 of TTD stock 5 years ago, it would be worth $492.52 today based on a price ...

Teledyne Technologies TDY -0.64% Get Free Report has outperformed the market over the past 20 years by 6.42% on an annualized ...

Shares of JM Smucker were trading at $113.3 as of November 21. Over the last 52-week period, shares are up 3.39%. Given that these returns are generally positive, long-term shareholders are likely ...

Buying $1000 In WING: If an investor had bought $1000 of WING stock 5 years ago, it would be worth $4,220.00 today based on a ...

Enveric Biosciences completed preclinical PK studies for EB-003, a DMT analog targeting depression and anxiety without ...

BBWI shares up after reporting better than expected Q3 results and raising 2024 outlook. Sales and earnings beat analyst estimates.

The earnings results for Alarum Technologies ALAR for Q3 were made public on Monday, November 25, 2024 at 07:30 AM. Here's a comprehensive overview of the announcement. Alarum Technologies beat ...

Shares of Cassava Sciences, Inc. SAVA -84.4% + Free Alerts fell sharply in today's pre-market trading after the company ...

Palantir Technologies Inc. PLTR +3.51% Get Free Report experienced a 3.25% increase in pre-market trading on Monday, as per ...